Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.66 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.62 |
| ▸ | GSK3A | P49840 | 2/20 | 0.62 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.62 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.62 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.62 |
| ▸ | PRKACA | P17612 | 2/20 | 0.62 |
| ▸ | CDK8 | P49336 | 2/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22926416 | 0.88 | JAK2 (0.75) | DYRK1ACLK4KDRJAK2RET | |
| SCHEMBL16621291 | 0.88 | DYRK1A (0.62) | DYRK1ACLK4KDRJAK2RET | |
| SCHEMBL22688959 | 0.84 | KDR (0.59) | DYRK1ACLK4KDRJAK2RET | |
| SCHEMBL3514678 | 0.83 | DYRK1A (0.70) | DYRK1ACLK4KDRJAK2RET | |
| SCHEMBL16562600 | 0.83 | CLK4 (0.61) | DYRK1ACLK4KDRJAK2RET | |
| Hydrochloric Acid SCHEMBL21411936 | 0.82 | DYRK1A (0.68) | DYRK1ACLK4KDRJAK2RET | |
| SCHEMBL360789 | 0.81 | DYRK1A (0.77) | DYRK1ACLK4KDRJAK2RET | |
| SCHEMBL21643997 | 0.80 | DYRK1A (1.00) | DYRK1ACLK4KDRJAK2RET | |
| SCHEMBL12970527 | 0.79 | DYRK1A (0.64) | DYRK1ACLK4KDRJAK2RET | |
| SCHEMBL16562548 | 0.77 | AURKA (1.00) | DYRK1ACLK4KDRJAK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| EP-4553068-A1 | PYRIMIDINE DERIVATIVES | ASKA Pharmaceutical Co., Ltd. (JP) | 2025-05-14 | — | — | EP | disclosed |
| CN-119497709-A | Pyrimidine derivatives | ASKA 制药株式会社 | 2025-02-21 | — | — | CN | disclosed |
| CN-111978325-B | Imidazopyridazine MNK1/MNK2 kinase inhibitor, and preparation method and application thereof | 中国药科大学 | 2023-11-17 | — | — | CN | disclosed |
| EP-3052501-B1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2022-06-22 | — | — | EP | disclosed |
| EP-3052501-B1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2022-06-22 | — | — | EP | disclosed |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-06-22 | — | — | US | disclosed |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-06-22 | — | — | US | disclosed |
| CN-111978325-A | Imidazopyridazine MNK1/MNK2 kinase inhibitor and preparation method and application thereof | 上海道熵生物科技有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20150038506-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-02-05 | — | — | US | disclosed |
| EP-2831079-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2015-02-04 | — | — | EP | disclosed |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-12-18 | — | — | US | disclosed |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-12-18 | — | — | US | disclosed |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-12-18 | — | — | US | disclosed |
| WO-2013147711-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013147711-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-03 | — | — | WO | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038506-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, NEK2, MKNK2 | DYRK1A 206/4885CLK4 55/4885KDR 3449/4885 |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | PTGES, PTGS1, PTGIS | DYRK1A 4220/4885CLK4 4399/4885KDR 2895/4885 |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | DYRK1A 2632/4885CLK4 938/4885KDR 1462/4885 |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | MKNK2, MKNK1, MAPKAPK2 | DYRK1A 758/4885CLK4 234/4885KDR 3042/4885 |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | DYRK1A 433/4885CLK4 133/4885KDR 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.